CytoDyn has published a press release regarding the leronlimab efficacy preclinical study for MASH/fibrosis provided by SMC
CytoDyn Inc., which is our client, has announced the results of pharmacology study using a STAM™ mouse model.
Resmetriom has been included in this pharmacology study, and its efficacy in treating fibrosis is directly compared with that of leronlimab.
For detail information, see the CytoDyn’s press release.
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories :: CytoDyn Inc. (CYDY)